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Evaluation of a Long-Acting Converting Enzyme Inhibitor (Enalapril)
for the Treatment of Chronic Congestive Heart Failure
ROBERT J. CODY, MD, FACC, ANDREW B. COVIT, MD, GARY L. SCHAER, MD,
JOHN H. LARAGH, MD, FACC
New York. New York
Converting enzyme inhibition of the renin-angiotensin
system has proved a valuable therapeutic approach in
patients with severe chronic congestive heart failure. In
the present study, a new long-acting converting enzyme
inhibitor (enalapril) was evaluated with acute single dose
testing (10, 20 or 40 mg) in nine patients with severe
chronic congestive heart failure. Four hours after
administration, there was a significant reduction of sys-
temic vascular resistance ( -19%) and pulmonary wedge
pressure (-19%); in addition, there were related in-
creasesofcardiac index (+16%)and stroke index(+19%)
(probability [p] ~ 0.05 for all changes). This was as-
sociated with an increase of plasma renin activity (9 ±
3 to 35 ± 11 ng/ml per hour) and a decrease of plasma
aldosterone (19 ± 4 to 9 ± 2 ng/l00 ml) (p < 0.02 for
both). With long-term therapy (1 month), there was im-
provement of exercise tolerance time and lessening of
symptoms based on the New York Heart Association
In severe chronic congestive heart failure, activation of the
renin-angiotensin system may represent a compensatory
mechanism to maintain perfusion pressure (1,2). As heart
failure persists, however, angiotensin-mediated vasocon-
striction and aldosterone-mediated sodium retention result
in progression of the congested state. Several studies have
demonstrated the short- and long-term benefits of converting
enzyme inhibition in this situation (3-5). Recently, a long-
acting oral converting enzyme inhibitor, enalapril (MK-
421), has become available for use (6). This orally active
compound is an ethyl ester converting enzyme inhibitor that
undergoes deesterification to the physiologically active form
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classification. Hemodynamic improvement was main-
tained in most, but not all, patients. There was no or-
thostatic hypotension during head-up tilt and hemody-
namic values in the upright position were associated with
normalization of intracardiac pressures. Long-term con-
verting enzyme inhibition was indicated by a persistent
increase of plasma renin activity (16 ± 2 ng/ml per hour)
and a decrease of plasma aldosterone (8 ± 3 ng/l00 mI).
In addition, relative angiotensin II receptor occupancy
was decreased as judged by the pharmacodynamic re-
sponse to infusion of the angiotensin II analog saralasin.
In conclusion, the long-acting converting enzyme in-
hibitor, enalapril, was effective in patients with chronic
congestiveheart failure; however, additional studies will
be necessary to further delineate the optimal dose range
and identify those patients who are most likely to respond
to the drug.
(MK-422), Its theoretical advantages over captopril are a
longer duration of action (7) and potential for fewer side
effects because the active compound does not contain a
sulfhydryl group (8). In a pilot study, we evaluated the short-
and long-term hemodynamic effects of this agent in patients
with severe congestive heart failure, focusing on the hemo-
dynamic and hormonal responses. In addition, we evaluated
the response to upright posture and the ability of enalapril
to decrease angiotensin II receptor occupancy, as judged by
the pharmacodynamic response to infusion of the angioten-
sin II analog saralasin.
Methods
Study patients. The study group consisted of nine patients
with severe chronic congestive heart failure. All patients were
normotensive, and none had ex.perienced myocardial infarction
during the previous 6 months. There were eight men and one
woman ranging in age from 45 to 80 years. Six. patients had
ischemic and three patients had nonischemic causes for their chronic
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congestive heart failure. On the basis of symptoms, seven patients
were in functional class IV and two patients were in functional
class III congestive heart failure by the New York Heart Associ-
ation classification. After giving informed consent, patients were
admitted to the metabolic ward for a lead-in period of at least 4
days before hemodynamic study. Patients were maintained on a
100 mEq sodium diet; they also underwent treadmill exercise test-
ing to fatigue, using a modified Naughton protocol. Because of
the severity of their heart disease, all patients were maintained on
digoxin and diuretic therapy with neither drug administered on the
morning of the hemodynamic study.
Acute hemodynamic study. Hemodynamic study was per-
formed in the morning after an overnight fast as previously de-
scribed (9). Right heart catheterization was performed to measure
intracardiac pressures and cardiac output by the thermodilution
technique. A cannula was placed in a peripheral artery for con-
tinuous recording of systemic arterial pressure. A precordial elec-
trocardiographic lead was used for continuous recording of the
heart rate, which was expressed as beats per minute. All pressures
were recorded as both phasic and electronically damped mean
values. Each determination of cardiac output was measured three
times and expressed as cardiac index, correctmg for body surface
area. Both systemic and pulmonary vascular resistance values were
calculated by standard formulas (9). After placement of the cath-
eters, a I hour equilibration period ensued in which baseline vari-
ables were recorded. These consisted of supine hemodynamic data
and 60° head-up tilt hemodynamic data. The latter were obtained
to assess orthostatic hypotension and the reflex adjustment to up-
right posture (5,10).
I'lfusion ofsaralasin. Significant interpatient variability of renin-
angiotensin system activity may occur in chronic heart failure (II).
As a rapid means to estimate this activity, administration of an
angiotensin II analog such as saralasin can be used to assess relative
angiotensin II receptor occupancy (12-15); that is, in patients with
normal or suppressed endogenous angiotensin II receptor activity,
infusion of saralasin will result in an agonist or pressor response,
whereas patients with high renin-angiotensin system activity and
angiotensin II receptor occupancy will demonstrate an antagonist
or depressor response. Therefore, we administered saralasin as a
constant infusion in standard doses (1.0 or 3.0 f.Lg/kg per min for
15 minutes) in all of the patients during the baseline period. This
infusion rate is sufficient to reveal angiotensin II receptor activity
(13-15). The infusion was not only to estimate the degree of
baseline renin-angiotensin system activity, but also to provide a
means of estimating angiotensin II receptor activity during long-
term enalapril inhibition of endogenous angiotensin II production.
After all baseline determinations, a reequilibration penod of 30 to
60 minutes passed, baseline measurements were again obtained
and enalapril administered.
Dosage of enalapril. Clinical data regarding the optimal dose
of enalapril are limited (16,17); however, in hypertensive patients,
an acute reduction of blood pressure can occur with an oral dose
as small as 2.5 mg. Because of these limited dose-response data,
a wide range of high dose enalapril was used in this pilot study,
with patients receiving 10 mg (two patients), 20 mg (five patients)
or 40 mg (two patients) as a single oral dose. The hemodynamic
response was monitored with recordings taken at hourly intervals
for at least 4 hours after drug administration. In addition, blood
samples for plasma renin activity and plasma aldosterone were
obtained at I hour intervals after drug administration. After the
acute hemodynamic response, patients were placed on long-term
therapy with enalapril in a total daily dose equal to the acute dose,
namely, 10 mg (four patients), 5 mg (two patients) or 2.5 mg (one
patient), administered twice daily. The latter patient was given a
smaller dose because of significant hypotension at higher doses.
Patients were monitored clinically in the hospital for the first 3
days of drug therapy, discharged on long-term therapy and read-
mitted at I month for follow-up study.
Long-term hemodynamic study. Of the nine patients in the
study group, only seven underwent long-term hemodynamic study,
because one patient was lost to follow-up and another died sud-
denly before the I month study. For the long-term study, all seven
patients continued on their maintenance dose of digoxin, diuretic
agent and enalapnl. Clinical evaluation was obtained, treadmill
exercise testing performed and hemodynamic study in the supine
and tilt positions performed 3 to 5 hours after the morning dose.
Because long-term converting enzyme inhibition would be ex-
pected to result in marked reduction of circulating endogenous
angiotensin II and angiotensin II receptor occupancy, administra-
tion of saralasin in this setting should result in an agonist or pressor
response if the receptor was relatively unoccupied. Therefore, all
patients received a constant infusion of saralasin at a rate identical
to that of the baseline study, and the hemodynamic response was
recorded. After this aspect of the study, the catheters were removed
and the patients subsequently discharged.
Hormonal assay. Plasma renin activity was estimated by a
radioimmunoassay technique as the generation of angiotensin I in
vitro, expressed as ng/ml per hour, as previously described by our
laboratory (18). Likewise, samples for plasma aldosterone were
obtained and analyzed by a radioimmunoassay technique (19) and
expressed as ngll 00 ml.
Statistical analysis. Statistical analysis of the hemodynamic
and hormonal response to short- and long-term enalapril therapy
was by analysis of variance with Newman-Keuls multiple rank
testing (20). Analysis of the response to tilt and saralasin infusion
was by paired t test. All values expressed represent mean values
:!:: I standard error of the mean. Changes were considered to be
statistically significant at a value of p < 0.05.
Results
Acute Response to Enalapril
For the group, baseline hemodynamic values indicated
severe chronic congestive heart failure (Table 1). This was
reflected by increased pulmonary wedge pressure (21 ± 2
mm Hg), increased systemic vascular resistance (1687 ±
128 dynes/s-cm -5) and decreased cardiac index (1.56 ±
0.08 liters/min per rrr') and stroke index (21 ± 3 ml/rrr').
There was also pulmonary hypertension and right ventricular
failure as indicated by a pulmonary artery pressure of 32
± 2 mm Hg and right atrial pressure of 11 ± 2 mm Hg,
respectively. For the group, plasma renin activity and al-
dosterone were also abnormally elevated at 9 ± 3 ng/ml
per hour and 19 ± 4 ng/IOO ml, respectively.
After oral administration of enalapril, there was a trend
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Table 1. Acute Hemodynamic Response to Enalapril in Nine Patients WithChronic Heart Failure
Baseline I Hour 2 Hours 3 Hours 4 Hours
HR (beats/min) 80 ± 5 81 ± 5 81 ± 6 80 ± 5 77 ± 5
AP (mm Hg) 74 ± 3 75 ± 4 72 ± 5 68 ± 4 * 67 ± 4*
RA(mm Hg) 11 ± 2 12 ± 2 10 ± 2 9 ± 2 9 ± 2
PA(mm Hg) 34 ± 2 36 ± 3 35 ± 2 33 ± 2 32 ± 2
PWP(mm Hg) 21 ± 2 21 ± 2 18 ± 2 17 ± 2 17 ± 2*
CI (hters/min per rrr') 1.56 ± 0.08 1.69 ± 0.09 1.73 ± 0.11 1.73 ± 0.13 1.81 ± 0.13*
SI (ml/m-) 21 ± 3 22 ± 3 22 ± 4 23 ± 3 25 ± 2*
SVR (dynes/s-cmt ") 1,687 ± 128 1,552 ± 110 1,520 ± 165 1,459 ± 163 1,378 ± 172*
PVR (dynes/s-cmr ') 362 ± 64 378 ± 48 411 ± 52 375 ± 43 354 ± 52
• Probability (p) :5 0.05
AP= mean artenal pressure; CI = cardiac index, HR = heart rate; PA= mean pulmonary artery pressure, PVR = pulmonary vascular resistance, PWP= mean pulmonary
wedge pressure; RA= mean right arterial pressure, SI = stroke index; SVR = systemic vascular resistance
significant increase in cardiac index to 1.81 ± 0.08 liters/
min per m2 and stroke index that increased to 24 ± 1 ml
per m". In most patients, there was long-term reduction in
pulmonary wedge pressure; however, this reduction did not
achieve statistical significance for the group because Patient
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Figure 1. Acute convernng enzyme inhibition and blockade of the renin-
angiotensin system after short-term administration of enalapril. Both the
mcrease III plasma rerun activity (ng/ml per hour) and decrease in plasma
aldosterone (ngllOO m!) were significant (p < 0.02).
100
80
Long-term Response to Enalapril
For the seven patients maintained on enalapril therapy
for 1 month, there was improvement in exercise tolerance
time and functional class (Fig. 2). Exercise time increased
from 122 ± 61 to 344 ± 90 seconds (p < 0.02). Functional
class improved by two classes in two patients and by one
class in four patients; it was unchanged in one patient.
The hemodynamic improvement at 1 month for the group
and for individual patients is shown in Table 2. Compared
with the control phase, there was a significant reduction in
mean arterial pressure (65 ± 1 mm Hg) and reduction of
systemic vascular resistance (l,317 ± 60 dynes/s-cm -5).
The reduction in systemic resistance was associated with a
of hemodynamic improvement over the first 2 hours; how-
ever, significant hemodynamic changes were not manifest
until 4 hours after drug administration. At that time, there
was reduction of mean arterial pressure to 67 ± 4 mm Hg
(p < 0.02). This was associated with a decrease in pul-
monary wedge pressure to 17 ± 2 mm Hg (p < 0.05) and
a decrease of systemic vascular resistance to 1,378 ± 172
dynes/s-cmr' (p < 0.01) (see Table 1). The reduction of
systemic resistance was associated with an increase in car-
diac index to 1.81 ± 0.13 liters/min per rrr' (p < 0.02) and
stroke index to 25 ± 2 mllper m2 (p < 0.01). Evidence of
converting enzyme inhibition was revealed by the reflex
increase of plasma renin activity to 35 ± 11 ng/ml per hour
and decrease of plasma aldosterone to 9 ± 2 ng/lOO ml,
both p < 0.02 (Fig. 1). Baseline plasma renin activity was
correlated with the percent decrease of systemic vascular
resistance (r = 0.670) and percent increase of cardiac index
(r = 0.684) at 4 hours after enalapril administration (p <
0.05 for both). Hemodynamic measurements were also ob-
tained at 6 and 8 hours in several patients in whom evidence
of hemodynamic improvement persisted. In five patients,
repeat hemodynamic measurements were made at 24 hours,
at which time there was no evidence of residual hemody-
namic changes.
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and reduction in plasma aldosterone to 8 ± 3 ng/ I00 ml (p
< 0.05) compared with control.
The hemodynamic response to upright posture was also
evaluated at 1 month of enalapril therapy (Table 3). No
orthostatic hypotension was observed despite significant re-
duction in cardiac filling pressures during head-up tilt. In
addition to supine hemodynamic improvement, the upright
hemodynamic data during long-term enalapril therapy were
better than both supine and tilt hemodynamic data during
the control phase.
Effects of saralasin infusion. To determine the extent
of angiotensin II receptor vacancy due to reduction of cir-
culating angiotensin II by enalapril, saralasin was infused
(Fig. 3). The response during the control phase was het-
erogeneous because of interpatient variability of renin-an-
giotensin system activity and, therefore, angiotensin II re-
ceptor activity. After 1 month of enalapril therapy, however,
when endogenous angiotensin II generation was blocked at
the converting enzyme, the response to saralasin was uni-
formly agonistic: there was a 20% increase in systemic
vascular resistance (p < 0.01), resulting in a 10% increase
in arterial pressure (p < 0.05). Because of the increased
systemic resistance, there was an increase in pulmonary
capillary wedge pressure ( +30%, P < 0.001) and a decrease
in cardiac index (- 25%, P < 0.001). This agonist response
to saralasin during enalapril therapy provided further evi-
dence that endogenous angiotensin II generationwas inhibited.
3 had an increase of pulmonary wedge pressure at I month
of enalapril therapy compared with the control phase. Over-
all, there was no significant change in heart rate, right atrial
and pulmonary artery pressures or pulmonary vascular re-
sistance at 1 month. Evidence for chronic converting en-
zyme inhibition for the group was a persistent increase in
plasma renin activity to 16 ± 2 ng/ml per hour (p < 0.05)
NYHA
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Figure 2. Improvement of exercise tolerance time (p < 0.02) and New
York Heart Association (NYHA)funcnonal classification after I monthof
enalapril therapy
Table 2. Long-term Response to Enalapril in Seven Patients With Chronic Heart Failure
Patient HR AP RA PA PWP CI SI SVR PVR
Control
I 85 84 9 40 18 1.33 16 2,400 704
2 93 80 18 36 25 1.30 14 2,112 352
3 64 80 13 25 17 1.60 25 1,536 176
4 104 72 18 46 32 1.20 12 1,720 440
5 58 61 4 36 26 1.85 32 1,208 208
6 80 66 6 24 12 1.91 24 1,224 240
7 77 62 10 28 20 1.60 21 1,511 237
Mean 80 72 11 34 22 1.54 20 1,673 337
SEM ±6 ±4 ±2 ±3 ±3 ± 0.10 ±3 ± 168 ±70
I Month
1 77 68 1 29 15 2.09 27 1,384 288
2 85 64 10 40 18 1.91 23 1,216 488
3 60 67 12 34 25 1.44 24 1,376 224
4 93 70 11 40 24 1.75 19 1,296 344
5 61 60 7 28 14 1.75 29 1,184 304
6 92 62 6 20 11 1.95 21 1,151 248
7 70 64 4 27 14 1.81 26 1,610 349
Mean 77 65 7 31 17 1.81 24 1,317 321
SEM ±5 ±1 ±2 ±3 ±2 ±0.08 ±I ±60 ±33
p* NS 0.05 NS NS NS 0.05 0.05 0.05 NS
'Significance at I month versus control
NS = not significant, p = probability, SEM = standard error of the mean: other abbreviations and umts as In Table 1
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Figure 3. The agonist/antagonist saralasin (SAR) was used to assess an-
giotensin II receptor occupancy in patients with heart failure who subse-
quently received long-term therapy with enalapril. In the baseline state
(len), there were varied hemodynamic responses to saralasin due to the
interpatient range of plasma renin activity. With I month of enalapril
therapy (r ight), a uniform agonist or pressor response was observed in all
patients. indicating significant reduction of endogenous angiotensin II gen-
eration . Asterisks indicate significant hemodynam ic changes. AP =~
arterial pressure (mm Hg); CI = cardiac index (liters/min per m' ); PCW
= mean pulmonary capillary wedge pressure (mm Hg); SVR = systemic
vascular resistance (dynes/s-cm -5) .
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as judged by pharmacologic stimulation of the receptor .
After the I month study, five patients were maintained on
enalapril therapy, prazosin was added to enalapril in a sixth
patient and enalapril was discont inued in a seventh patient
because of poor response.
Therapeutic implications. This study represents a pilot
study of this new long-acting converting enzyme inhibitor
in patients with chronic heart failure. Several points are
noted as a result of these initial data. First , the delayed onset
of enalapril action and its prolonged effect obscure the peak
response and duration of action , so that continuous hemo-
dynamic and hormonal monitoring for at least 12 hours
would be required . This is difficult not only in terms of
patient tolerance , but also because of changes in baseline
hemodynamic values and diurnal variation in renin release
(22). Second, the optimal dose of enalapril is not clear,
Table 3. Effect of Long-term Enalapril on Postural
Hemodynamics
Discussion
Side effects and dosage. Long-term use of enalapril was
associated with subjective and objective improvement in
most of our patients . There were no major side effects during
this period of observation, and one of the seven patients
with asymptomatic hypoten sion required downward adjust-
ment of his enalapril dosage. The death of one patient that
occurred during the period of observation was a sudden
death in a person with documented high grade ventricular
ectopic rhythm. Effective daily dosage ranged from 2.5 to
10 mg, administered twice daily. The range of dosage was
associated with hemodynamic improvement and hormonal
evidence of complete converting enzyme inhibition , and was
similar to the dosage used thus far in patients with hyper-
tension (16 ,17).
Acute effects. During the short-term study, significant
hemodynamic changes were observed at 4 hours. Therefore,
this may represent the peak effect or the peak effect may
actually occur somewhat after this period of time (7,17) .
Unlike captopril, whose peak hemodynamic and hormonal
effect occurs 1 to 1.5 hours after administration (21), the
effect of enalapril would be expected to peak later because
the drug is administered in a prodrug form and has to undergo
deesterification to the active compound (6,7).
Long-term effects. Enalapril was continued on a long-
term basis with digoxin and diuretic therapy, and most pa-
tients demonstrated lessening of symptoms and increased
exercise tolerance. In most patients, there was a reduction
of systemic vascular resistance and an increase of cardiac
index; however , this was not uniform . For the group, the
response to upright tilt was notable for absence of orthostatic
hypotension, improvement of supine and upright hemody-
namic status compared with the control state and, particu-
larly, normalization of card iac filling pressures in the upright
position. Persistent converting enzyme inhibition was in-
dicated by increased plasma renin activity, decreased plasma
aldosterone and reduced angiotensin II receptor occupancy
Control I Month AP
Supine Tilt Supine Tilt
HR 8 1 ± 6 85 ± 5 77 ± 5 82 ± 5
AP 72 ± 3 65 ± I 65 ± I 63 ± 4
RA II ± 2 * 4 ± 2 7 ± 2 * 3 ± 2
PA 35 ± 3 * 23 ± 5 3 1 ± 3 * 24 ± 4 pcw
PWP 20 ± 3 * II ± 4 I7 ± 2 *. 12 ± 3
CI 1.60 ± 0. 14 1.49 ± 0. 10 1.81 ± 0.08 1.66 ± 0.07
SI 21 ± 3 19 ± 2 24 ± I 22 ± 2
SVR 1,643 ± 203 1,704 ± 183 1,317 ± 60 1,476 ± 90
• Asterisks indicate a significance level of at least p <0.05.
Abbreviations and unitsas in Table I.
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although animal studies (7) demonstrate that relatively small
doses are sufficient to block the pressor effect of exoge-
nously administered angiotensin I. From the present study,
it would appear that a dose of 10 or 20 mg administered
for a short period of time, and 5 or 10 mg administered
twice daily should be sufficient to inhibit the angiotensin-
converting enzyme in most patients. This conclusion is drawn
from the evidence of blockade of aldosterone production
and reduction of angiotensin II receptor occupancy as judged
by pharmacologic stimulation of the receptor.
These points will require additional studies for clarifi-
cation. Furthermore, because the peak response to enalapril
is difficult to identify in this short-term study, it was difficult
to correlate the extent of hemodynamic improvement with
baseline plasma renin activity as has been done in previous
studies of converting enzyme inhibitors (8). It has become
evident that interruption of angiotensin II-mediated vaso-
constriction and aldosterone-mediated sodium retention is
an important facet of the therapeutic approach to severe
chronic congestive heart failure. Therefore, continued stud-
ies of enalapril regarding both its pharmacodynamic and
physiologic effects seem warranted.
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